Folac

class="Serp__item__snippet--34vQF">Compared with warfarin, apixaban was associated with a greater benefit on the composite endpoints in patients with active cancer than in those without cancer. Conclusion: There was no evidence of a lesser effect of apixaban vs. warfarin in patients with active...